PET Measures of CSF Clearance in Preclinical Alzheimer's Disease

临床前阿尔茨海默氏病脑脊液清除率的 PET 测量

基本信息

  • 批准号:
    10085704
  • 负责人:
  • 金额:
    $ 284.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-15 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Recent transgenic mouse studies have highlighted impaired glymphatic function as potentially involved in the pathophysiology of Alzheimer's disease (AD). We learn from these studies that a reduced clearance of CSF, which carries Aβ and other waste products, needs to be considered in the development of amyloid plaques and possibly the pathophysiology of Alzheimer's. These observations complement well characterized trans- membrane Aβ clearance impairments in Alzheimer's. Lumbar puncture studies have confirmed an impaired clearance of Aβ to the CSF in AD patients. However, lumbar puncture studies do not distinguish between an impaired transport of Aβ across membranes from impairments in the bulk flow of CSF, which transports the Aβ. We developed the first non-invasive technology to quantify human CSF clearance. The technique uses PET to dynamically image a low molecular weight tau tracer with high brain penetrance, rapid clearance, and limited residual brain uptake. Our preliminary data demonstrate that after controlling for blood tracer levels, PET estimates of CSF clearance are highly reproducible within subject and across tau and amyloid PET tracers. CSF clearance achieves 89% accuracy for the diagnosis of AD. Most importantly, our results show that reduced tau tracer clearance measured at the ventricle and the cingulate gyrus (a major target for Aβ deposits) is closely associated with the magnitude of brain Aβ deposits as measured by PiB-PET. This strong inverse relationship between clearance and Aβ deposition is also found in normal elderly (NL) at both region and voxels levels. These observations justify our prospective longitudinal study of the relationship between CSF clearance, Aβ lesion progression, brain atrophy and cognitive decline. The study will enroll two age and gender matched NL elderly groups: amyloid-positive and amyloid-negative controls. Our preliminary data also revealed that the superior nasal turbinates are a CSF egress pathway in humans. This novel observation requires further anatomical and histological validation, which we propose to collect in an exploratory study. In sum, using a novel PET method to quantify the drainage of CSF from the human brain, we have the first opportunity to test the hypothesis that impaired CSF clearance facilitates Aβ propagation in preclinical Alzheimer disease.
摘要 最近的转基因小鼠研究强调了受损的胶质淋巴功能可能参与了 阿尔茨海默病(AD)的病理生理学。我们从这些研究中了解到,CSF清除率降低, 携带Aβ和其他废物,需要在淀粉样斑块的发展中考虑 可能还有阿尔茨海默氏症的病理生理学这些观察结果补充了良好的特征性反式- 阿尔茨海默氏症中的膜Aβ清除障碍腰椎穿刺研究已经证实 AD患者CSF中Aβ的清除率。然而,腰椎穿刺研究并不能区分 由于运输Aβ的CSF整体流量受损,导致A β跨膜转运受损。 我们开发了第一种非侵入性技术来量化人类CSF清除率。该技术使用PET, 动态成像低分子量tau示踪剂,其具有高脑转移率、快速清除和有限的 残留脑摄取我们的初步数据表明,在控制血液示踪剂水平后,PET CSF清除率的估计值在受试者内以及在tau和淀粉样蛋白PET示踪剂之间是高度可重复的。 CSF清除率诊断AD的准确率达到89%。最重要的是,我们的研究结果表明, 在脑室和扣带回(Aβ沉积的主要靶点)测量的tau示踪剂清除率降低 与PiB-PET测量的脑Aβ沉积量密切相关。这个强逆 在正常老年人(NL)中也发现了清除率与Aβ沉积的关系, 体素水平。这些观察结果证明了我们对CSF与脑梗死之间关系的前瞻性纵向研究是正确的。 清除、Aβ病变进展、脑萎缩和认知能力下降。该研究将招募两名年龄和性别 匹配的NL老年组:淀粉样蛋白阳性和淀粉样蛋白阴性对照。我们的初步数据还显示 上级鼻甲是人类脑脊液的排出通道。这种新的观察需要 进一步的解剖学和组织学验证,我们建议在探索性研究中收集。总的来说, 使用一种新的PET方法来量化从人脑中排出的CSF,我们有机会 检验CSF清除率受损促进临床前阿尔茨海默病中Aβ传播的假设。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Association between liver fibrosis and incident dementia in the UK Biobank study.
Tau PET following acute TBI: Off-target binding to blood products, tauopathy, or both?
急性 TBI 后的 Tau PET:与血液制品的脱靶结合、tau 蛋白病变,或两者兼而有之?
  • DOI:
    10.3389/fnimg.2022.958558
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Butler,Tracy;Chiang,GloriaC;Niogi,SumitNarayan;Wang,XiuyuanHugh;Skudin,Carly;Tanzi,Emily;Wickramasuriya,Nimmi;Spiegel,Jonathan;Maloney,Thomas;Pahlajani,Silky;Zhou,Liangdong;Morim,Simon;Rusinek,Henry;Normandin,Marc;Dyke,Jona
  • 通讯作者:
    Dyke,Jona
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MONY J. de LEON其他文献

MONY J. de LEON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MONY J. de LEON', 18)}}的其他基金

PET Measures of CSF Clearance in Preclinical Alzheimer's Disease
临床前阿尔茨海默氏病脑脊液清除率的 PET 测量
  • 批准号:
    9429344
  • 财政年份:
    2017
  • 资助金额:
    $ 284.48万
  • 项目类别:
Maternal history of Alzheimer's predisposes children to amyloid beta-related hy
母亲患有阿尔茨海默氏病史使儿童容易患上淀粉样蛋白β相关的疾病
  • 批准号:
    7984348
  • 财政年份:
    2010
  • 资助金额:
    $ 284.48万
  • 项目类别:
Maternal history of Alzheimer's predisposes children to amyloid beta-related hypo
母亲患有阿尔茨海默病史使儿童容易患淀粉样蛋白β相关性低下症
  • 批准号:
    8127753
  • 财政年份:
    2010
  • 资助金额:
    $ 284.48万
  • 项目类别:
BIOMARKERS IN EARLY ALZHEIMER'S DISEASE
早期阿尔茨海默病的生物标志物
  • 批准号:
    7718414
  • 财政年份:
    2008
  • 资助金额:
    $ 284.48万
  • 项目类别:
PREDICTORS OF COGNITIVE DECLINE IN NORMAL AGING
正常衰老过程中认知能力下降的预测因素
  • 批准号:
    7718402
  • 财政年份:
    2008
  • 资助金额:
    $ 284.48万
  • 项目类别:
CLINICAL CORRELATES OF LONGITUDINAL PET CHANGES IN ALZHEIMER'S DISEASE
阿尔茨海默病纵向 PET 变化的临床相关性
  • 批准号:
    7718404
  • 财政年份:
    2008
  • 资助金额:
    $ 284.48万
  • 项目类别:
CLINICAL CORRELATES OF LONGITUDINAL PET CHANGES IN NORMAL AGING
正常衰老过程中纵向 PET 变化的临床相关性
  • 批准号:
    7607905
  • 财政年份:
    2007
  • 资助金额:
    $ 284.48万
  • 项目类别:
BIOMARKERS IN EARLY ALZHEIMER'S DISEASE
早期阿尔茨海默病的生物标志物
  • 批准号:
    7605727
  • 财政年份:
    2007
  • 资助金额:
    $ 284.48万
  • 项目类别:
CLINICAL CORRELATES OF LONGITUDINAL PET CHANGES IN ALZHEIMER'S DISEASE
阿尔茨海默病纵向 PET 变化的临床相关性
  • 批准号:
    7607903
  • 财政年份:
    2007
  • 资助金额:
    $ 284.48万
  • 项目类别:
PREDICTORS OF COGNITIVE DECLINE IN NORMAL AGING
正常衰老过程中认知能力下降的预测因素
  • 批准号:
    7605708
  • 财政年份:
    2007
  • 资助金额:
    $ 284.48万
  • 项目类别:

相似海外基金

CAREER: Optimal Transport Beyond Probability Measures for Robust Geometric Representation Learning
职业生涯:超越概率测量的最佳传输以实现稳健的几何表示学习
  • 批准号:
    2339898
  • 财政年份:
    2024
  • 资助金额:
    $ 284.48万
  • 项目类别:
    Continuing Grant
Group Actions, Rigidity, and Invariant Measures
群体行动、刚性和不变措施
  • 批准号:
    2400191
  • 财政年份:
    2024
  • 资助金额:
    $ 284.48万
  • 项目类别:
    Standard Grant
Non-tariff measures and the Global Value Chains
非关税措施和全球价值链
  • 批准号:
    24K16361
  • 财政年份:
    2024
  • 资助金额:
    $ 284.48万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
CAREER: Information-Theoretic Measures for Fairness and Explainability in High-Stakes Applications
职业:高风险应用中公平性和可解释性的信息论测量
  • 批准号:
    2340006
  • 财政年份:
    2024
  • 资助金额:
    $ 284.48万
  • 项目类别:
    Continuing Grant
Conference: Geometry of Measures and Free Boundaries
会议:测量几何和自由边界
  • 批准号:
    2403698
  • 财政年份:
    2024
  • 资助金额:
    $ 284.48万
  • 项目类别:
    Standard Grant
Estimating Risk Measures, with Applications to Finance and Nuclear Safety
评估风险措施,并应用于金融和核安全
  • 批准号:
    2345330
  • 财政年份:
    2024
  • 资助金额:
    $ 284.48万
  • 项目类别:
    Standard Grant
Our health counts: population-based measures of urban Indigenous health determinants, health status, and health care access across two cities in New Brunswick
我们的健康很重要:新不伦瑞克省两个城市的城市土著健康决定因素、健康状况和医疗保健获取情况的基于人口的衡量标准
  • 批准号:
    489076
  • 财政年份:
    2023
  • 资助金额:
    $ 284.48万
  • 项目类别:
    Operating Grants
Primary care quality for older adults: practice-based quality measures derived from a RAND/UCLA appropriateness method study
老年人初级保健质量:源自兰德/加州大学洛杉矶分校适当性方法研究的基于实践的质量衡量标准
  • 批准号:
    495174
  • 财政年份:
    2023
  • 资助金额:
    $ 284.48万
  • 项目类别:
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 284.48万
  • 项目类别:
Development and validation of a composite measure of physical function using a battery of performance-based measures: A longitudinal analyses of the Canadian Longitudinal Study on Aging
使用一系列基于表现的测量方法开发和验证身体机能的综合测量方法:加拿大老龄化纵向研究的纵向分析
  • 批准号:
    499193
  • 财政年份:
    2023
  • 资助金额:
    $ 284.48万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了